The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia.
Although the zeta-associated protein of 70 kDa (ZAP-70) is overexpressed in patients with chronic lymphocytic leukemia (CLL) displaying unmutated IGVH genes and poor prognosis, a previous microarray study from our group identified overexpression of LPL and ADAM29 genes among unmutated and mutated CLL, respectively. To assess the prognostic value of these genes, we quantified their expression by real-time quantitative polymerase chain reaction (PCR) in a cohort of 127 patients with CLL and correlated this with clinical outcome, IGVH mutational status, and ZAP-70 protein expression. IGVH mutational status, ZAP-70, and the LPL and ADAM29 mRNA ratios (L/A ratio) were predictive of event-free survival for the whole cohort and for patients with stage A disease. In patients in stage B and C, the L/A ratio was an independent prognostic factor, whereas ZAP-70 did not predict survival. Simultaneous usage of the L/A ratio and ZAP-70 expression allowed an almost perfect (99%) assessment of the IGVH status in the 80% of patients with concordant results (L/A+, ZAP-70+ or L/A-, ZAP-70-). LPL and ADAM29 gene expression could also be determined by a simple competitive multiplex reverse transcription PCR assay. Overall, quantification of LPL and ADAM29 gene expression is a strong prognostic indicator in CLL, providing better prognostic assessment than ZAP-70 in advanced stages of the disease.
Oppezzo
Pablo
P
Unité d'Immuno-Hématologie et d'Immunopathologie, Institut Pasteur, Paris, France.
Vasconcelos
Yuri
Y
Settegrana
Catherine
C
Jeannel
Dominique
D
Vuillier
Françoise
F
Legarff-Tavernier
Magali
M
Kimura
Eliza Yuriko
EY
Bechet
Stéphane
S
Dumas
Gérard
G
Brissard
Martine
M
Merle-Béral
Hélène
H
Yamamoto
Mihoko
M
Dighiero
Guillaume
G
Davi
Frédéric
F
D051722:ADAM Proteins; D001483:Base Sequence; D014408:Biomarkers, Tumor / Q000235:genetics; D016022:Case-Control Studies; D018076:DNA, Complementary / Q000235:genetics; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D015870:Gene Expression; D005803:Genes, Immunoglobulin; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000201:enzymology* / Q000235:genetics*; D008071:Lipoprotein Lipase / Q000235:genetics*; D008297:Male; D008666:Metalloendopeptidases / Q000235:genetics*; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D015203:Reproducibility of Results; D020133:Reverse Transcriptase Polymerase Chain Reaction; D051746:ZAP-70 Protein-Tyrosine Kinase
D014408:Biomarkers, Tumor; D018076:DNA, Complementary; D004273:DNA, Neoplasm; D007143:Immunoglobulin Heavy Chains; D011505:Protein-Tyrosine Kinases; D051746:ZAP-70 Protein-Tyrosine Kinase; C497261:ZAP70 protein, human; D008071:Lipoprotein Lipase; D051722:ADAM Proteins; C122189:ADAM29 protein, human; D008666:Metalloendopeptidases